HSBC Holdings
AKBA icon

HSBC Holdings’s Akebia Therapeutics AKBA Stock Holding History

HSBC Holdings’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$206K Buy
+148,092
New +$204K ﹤0.01% 2600
2025
Q3 		– Sell
-28,309
Closed -$104K – 2702
2025
Q2 		$104K Sell
28,309
-42,525
-60% -$117K ﹤0.01% 2839
2025
Q1 		$135K Buy
70,834
+829
+1% +$1.69K ﹤0.01% 2731
2024
Q4 		$131K Buy
70,005
+15,032
+27% +$26.1K ﹤0.01% 2833
2024
Q3 		$72.6K Buy
+54,973
New +$73.4K ﹤0.01% 2845
2022
Q2 		– Sell
-69,107
Closed -$49K – 3218
2022
Q1 		$49K Sell
69,107
-25,028
-27% -$53.5K ﹤0.01% 3201
2021
Q4 		$215K Buy
94,135
+55,073
+141% +$150K ﹤0.01% 2994
2021
Q3 		$112K Hold
39,062
– – ﹤0.01% 2876
2021
Q2 		$148K Hold
39,062
– – ﹤0.01% 2803
2021
Q1 		$132K Sell
39,062
-13,062
-25% -$47K ﹤0.01% 2607
2020
Q4 		$146K Sell
52,124
-11,338
-18% -$33.1K ﹤0.01% 2894
2020
Q3 		$158K Buy
63,462
+35,532
+127% +$312K ﹤0.01% 2536
2020
Q2 		$379K Sell
27,930
-2,189
-7% -$22.6K ﹤0.01% 2004
2020
Q1 		$234K Buy
30,119
+4,264
+16% +$33.2K ﹤0.01% 2197
2019
Q4 		$168K Sell
25,855
-144,656
-85% -$688K ﹤0.01% 2850
2019
Q3 		$668K Buy
+170,511
New +$731K ﹤0.01% 2161

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

HSBC Holdings's AKBA Position: Q1 2026 in Review

HSBC Holdings opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 148,092 shares worth $206K. The stake represents ﹤0.01% of the portfolio and ranks #2600 among its holdings. This is a return to the name: HSBC Holdings previously reported a position in AKBA as recently as Q2 2025.

HSBC Holdings first reported a position in AKBA in Q3 2019 and has held it in 16 quarters since. The position peaked at $668K in Q3 2019. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • HSBC Holdings held 148,092 shares of Akebia Therapeutics worth $206K as of Q1 2026.
  • Akebia Therapeutics was a new HSBC Holdings position in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2600 holding.
  • HSBC Holdings first reported a position in Akebia Therapeutics in Q3 2019 and has held it in 16 quarters since.
  • HSBC Holdings's Akebia Therapeutics position peaked at $668K in Q3 2019.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.